A UN-backed programme shipping coronavirus vaccines to many poor countries has now delivered one billion doses.
But the milestone “is only a reminder of the work that remains” after hoarding and stockpiling in rich countries, the World Health Organisation said.
A shipment of 1.1 million Covid-19 vaccine doses to Rwanda on Saturday included the billionth dose supplied via the Covax programme, the UN health agency said.
It said that, as of Thursday, 36 of its 194 member countries had vaccinated less than 10% of their population and 88 had vaccinated less than 40%.
The programme has made deliveries to 144 countries so far, “but the work that has gone into this milestone is only a reminder of the work that remains”, the WHO said in a statement.
“Covax’s ambition was compromised by hoarding/stockpiling in rich countries, catastrophic outbreaks leading to borders and supply being locked,” it added.
“And a lack of sharing of licences, technology and know-how by pharmaceutical companies meant manufacturing capacity went unused.”
At the end of December, WHO director-general Tedros Adhanom Ghebreyesus urged everyone to make a “new year’s resolution” to get behind a campaign to vaccinate 70% of countries’ populations by the beginning of July.
“Unfortunately, there are still too few countries participating in the financing of the global vaccination campaign,” Svenja Schulze was quoted as telling the Funke newspaper group.
“Alongside Sweden, Norway, Canada and the US, we are the ones who are giving most. The other industrial countries have significant ground to catch up.”
Germany has said it donated 103 million doses to poorer countries last year and plans to donate another 75 million in 2022.
Ms Schulze signalled that she wants to expand help for developing countries to produce vaccines themselves, with partnerships between companies to produce vaccines under licence a favoured aim.
Asked whether it would make sense to waive patents on Covid-19 patents, which Germany’s previous government opposed, she replied: “I doubt that developing countries would get vaccines more easily if we waive the patents.”
The issue is only a small part of the production process, Ms Schulze argued.
